In the homecare post-acute respiratory care business, Viemed (NASDAQ:VMD) would seem to be well-positioned, but has gotten hammered alongside most everything else over the past few weeks.
CEO Casey Hoyt:
“We have modified our procedures to immediately focus on the health and
safety of our employees and existing patient base … We remain in
position to safely treat the growing patient base with our significant
ventilator fleet and our remote patient monitoring capabilities.”
Shares jumped as high as $3.40 earlier, but have pulled back to $2.87 at pixel time, up 5.5% on the session.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.